Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $9.98B | $92.95 | $91.00 | -2.10% | Buy | 5 | 38.96% | 140.20% | 189.22% | 148.15% | |||
| LQDA | LIQUIDIA CORP | $7.72B | $86.82 | $78.17 | -9.97% | Buy | 6 | 70.75% | 206.63% | 560.72% | 151.62% | |||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $38.27B | $286.62 | $416.23 | 45.22% | Strong Buy | 13 | 27.99% | 48.56% | 233.69% | 48.99% | |||
| XERS | XERIS BIOPHARMA HOLDINGS INC | $1.45B | $8.38 | $10.00 | 19.33% | Buy | 1 | 20.98% | 104.29% | 1,840.67% | 61.09% | |||
| HALO | HALOZYME THERAPEUTICS INC | $9.88B | $83.28 | $88.25 | 5.97% | Strong Buy | 4 | 14.00% | 55.88% | 525.51% | 43.18% | |||
| VCEL | VERICEL CORP | $2.38B | $46.62 | $62.00 | 32.99% | Strong Buy | 2 | 16.37% | 47.55% | 24.71% | 18.13% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.86B | $61.37 | $87.75 | 42.99% | Strong Buy | 16 | 15.06% | 67.74% | 26.32% | 19.03% | |||
| ASND | ASCENDIS PHARMA A | $15.66B | $252.05 | $302.70 | 20.10% | Strong Buy | 10 | 35.08% | 9.59% | 263.27% | 64.13% | |||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $6.31B | $80.92 | $89.14 | 10.16% | Strong Buy | 7 | 15.90% | 32.32% | 38.00% | 27.74% | |||
| RPRX | ROYALTY PHARMA PLC | $34.08B | $59.18 | $61.80 | 4.43% | Strong Buy | 5 | 16.43% | 47.60% | 41.61% | 20.87% | |||
| KRYS | KRYSTAL BIOTECH INC | $10.71B | $363.28 | $349.22 | -3.87% | Strong Buy | 9 | 27.18% | 19.54% | 67.55% | 61.74% | |||
| ADMA | ADMA BIOLOGICS INC | $2.02B | $8.71 | $17.50 | 100.92% | Strong Buy | 2 | 16.11% | 24.01% | 90.04% | 52.84% | |||
| TGTX | TG THERAPEUTICS INC | $8.19B | $53.48 | $57.25 | 7.05% | Buy | 4 | 33.34% | 6.94% | 104.97% | 40.04% | |||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $16.06B | $255.97 | $269.21 | 5.17% | Strong Buy | 14 | 6.44% | 296.35% | 44.09% | 16.85% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.08B | $35.86 | $39.67 | 10.62% | Hold | 6 | 13.89% | 25.69% | 25.36% | 18.15% | |||
| LGND | LIGAND PHARMACEUTICALS INC | $5.77B | $288.01 | $335.50 | 16.49% | Strong Buy | 6 | 17.50% | 22.87% | 28.31% | 18.43% | |||
| SPRO | SPERO THERAPEUTICS INC | $68.90M | $1.19 | N/A | N/A | N/A | N/A | -21.95% | 83.29% | N/A | N/A | |||
| TECH | BIO-TECHNE CORP | $11.28B | $72.03 | $67.44 | -6.37% | Hold | 9 | 8.37% | 54.53% | 19.73% | 16.13% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $122.67B | $483.33 | $554.82 | 14.79% | Strong Buy | 17 | 10.03% | 13.35% | 38.20% | 27.93% | |||
| EXEL | EXELIXIS INC | $13.91B | $55.33 | $51.80 | -6.38% | Hold | 10 | 11.57% | 13.31% | 64.63% | 48.24% | |||
| NAGE | NIAGEN BIOSCIENCE INC | $256.45M | $3.22 | $10.50 | 226.09% | Strong Buy | 2 | 14.48% | 10.87% | 35.52% | 25.58% | |||
| UTHR | UNITED THERAPEUTICS CORP | $22.27B | $524.70 | $651.10 | 24.09% | Strong Buy | 10 | 10.63% | 8.58% | 32.70% | 28.74% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $72.91B | $695.42 | $790.42 | 13.66% | Strong Buy | 19 | 9.31% | 14.67% | 24.71% | 19.00% | |||
| INCY | INCYTE CORP | $25.76B | $127.10 | $112.47 | -11.51% | Buy | 15 | 4.55% | 7.48% | 12.85% | 10.36% | |||
| VCYT | VERACYTE INC | $4.45B | $55.71 | $56.00 | 0.52% | Buy | 7 | 10.78% | 8.49% | 12.14% | 11.36% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.